4 unknown, 2 not yet recruiting, 1 completed, 1 enrolling by invitation. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Unknown 4, Not yet recruiting 2, Completed 1, Enrolling by invitation 1 |
| Phase 2 | 3 | Not yet recruiting 2, Unknown 1 |
Follow HLX10: new trials by email Literature Review of HLX10 trials Research Report on HLX10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors HLX43, HLX10 - Advanced/Metastatic Malignant Solid Tumors | Phase 1 | Enrolling by invitation | Shanghai Henlius Biotech | 367 | 2023-11-24 | 2026-10-13 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors HLX35, HLX10 - Solid Tumor, Adult | Phase 1 | Unknown | Shanghai Henlius Biotech | 30 | 2023-01-06 | 2022-07-05 |
| PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 40 | 2022-09-01 | 2022-08-15 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor HLX26, HLX10 - Adult Solid Tumor | Phase 1 | Completed | Shanghai Henlius Biotech | 9 | 2022-07-26 | 2024-02-06 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors HLX04, HLX10 - Solid Tumor | Phase 1 | Unknown | Shanghai Henlius Biotech | 30 | 2018-11-27 | 2019-05-23 |
| Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors HLX10 - Solid Tumor | Phase 1 | Unknown | Henlix, Inc | 30 | 2018-02-14 | 2020-06-01 |
Meningioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neurofibromatosis 2 (1) · Neuroma, Acoustic (1)
Shanghai Henlius Biotech (4) · Beijing Tiantan Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Henlix, Inc (1) · Second Affiliated Hospital of Soochow University (1)
China (4) · Japan (1) · Taiwan (1) · United States (1)
Gi-Ming Lai, MD (1) · Jie Wang, Dr. (1)